>
Switch to:

Allergy Therapeutics Enterprise Value

: $207.7 Mil (As of Today)
View and export this data going back to 2004. Start your Free Trial

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Allergy Therapeutics's Enterprise Value is $207.7 Mil. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil. Therefore, Allergy Therapeutics's EV-to-EBIT ratio for today is 35.70.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Allergy Therapeutics's Enterprise Value is $207.7 Mil. Allergy Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $11.6 Mil. Therefore, Allergy Therapeutics's EV-to-EBITDA ratio for today is 17.88.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Allergy Therapeutics's Enterprise Value is $207.7 Mil. Allergy Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2021 was $118.3 Mil. Therefore, Allergy Therapeutics's EV-to-Revenue ratio for today is 1.76.


Allergy Therapeutics Enterprise Value Historical Data

The historical data trend for Allergy Therapeutics's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allergy Therapeutics Annual Data
Trend Jun12 Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21
Enterprise Value
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 171.99 162.26 76.46 64.58 109.06

Allergy Therapeutics Semi-Annual Data
Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21
Enterprise Value Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 76.46 70.46 64.58 15.29 109.06

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Allergy Therapeutics Enterprise Value Distribution

For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Allergy Therapeutics's Enterprise Value falls into.



Allergy Therapeutics Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Allergy Therapeutics's Enterprise Value for the fiscal year that ended in Jun. 2021 is calculated as

Allergy Therapeutics's Enterprise Value for the quarter that ended in Jun. 2021 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics  (OTCPK:AGYTF) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Allergy Therapeutics's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=207.686/5.8176718092567
=35.70

Allergy Therapeutics's current Enterprise Value is $207.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2021 was $5.8 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Allergy Therapeutics's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=207.686/11.612903225806
=17.88

Allergy Therapeutics's current Enterprise Value is $207.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Jun. 2021 was $11.6 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Allergy Therapeutics's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=207.686/118.2762973352
=1.76

Allergy Therapeutics's current Enterprise Value is $207.7 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Revenue for the trailing twelve months (TTM) ended in Jun. 2021 was $118.3 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allergy Therapeutics Enterprise Value Related Terms

Thank you for viewing the detailed overview of Allergy Therapeutics's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Allergy Therapeutics Business Description

Allergy Therapeutics logo
Industry
Traded in Other Exchanges
Address
Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergy with aluminium-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany and other countries.

Allergy Therapeutics Headlines

No Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)